Physician
Hematology
Dr. Lowell L. Hart, MD
|
|
Give Review
Lowell Hart works in the field of Hematology. He went to medical school at State University of New York Upstate Medical University. He received 4 awards: "Gulfshore Life Magazine: Top Doctors", "CMS Meaningful Use Stage 1 Certification", "Top Doctors: Florida" and "Top MD". Doctor Lowell L. Hart, MD is a published physician as well. He has 30 publications published. The latest was: Small-cell lung carcinoma: an analysis of 194 consecutive patients. He is registered with Medicare and accepts Medicare payments.
Publications
- A randomized, placebo-controlled, phase 1/2 study of tivantinib (ARQ 197) in combination with irinotecan and cetuximab in patients with metastatic coloRectal cancer wi...
- Phase I/II Study of the Combination of Panobinostat and Carfilzomib in Patients with Relapsed/Refractory Multiple Myeloma.
- A randomized phase II study of the telomerase inhibitor imetelstat as maintenance therapy for advanced non-small cell lung Cancer.
- A phase Ib study of linsitinib (OSI-906), a dual inhibitor of IGF-1R and IR tyrosine kinase, in combination with everolimus as treatment for patients with refractory m...
- Phase I/II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Patients With Locally Advanced or Metastatic Breast Cancer.
- Phase 1/2 study of KRN330, a fully human anti-A33 monoclonal antibody, plus irinotecan as second-line treatment for patients with metastatic coloRectal cancer.
- Improved time to treatment failure with an intermittent oxaliplatin strategy: results of CONcePT.
- Phase I/II Trial of Orteronel (TAK-700)--an Investigational 17,20-Lyase Inhibitor--in Patients with Metastatic Castration-Resistant Prostate Cancer.
- Everolimus plus exemestane as first-line therapy in HR(+), HER2 (-) advanced breast Cancer in BOLERO-2.
- Addition of bevacizumab to three docetaxel regimens as adjuvant therapy for early stage breast Cancer.
- Effect of visceral metastases on the efficacy and safety of everolimus in postmenopausal women with advanced breast cancer: Subgroup Analysis from the BOLERO-2 study.
- Effect of Everolimus on Bone Marker Levels and Progressive Disease in Bone in BOLERO-2.
- Phase II study evaluating lapatinib in combination with nab-paclitaxel in HER2-overexpressing metastatic breast Cancer patients who have received no more than one prio...
- A randomized phase II trial of vismodegib versus placebo with FOLFOX or FOLFIRI and bevacizumab in patients with previously untreated metastatic coloRectal cancer.
- A multicenter, phase 2 study of vascular endothelial growth factor trap (Aflibercept) in platinum- and erlotinib-resistant adenoCarcinoma of the lung.
- Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lu...
- Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic coloRectal cancer: results of the TR...
- Treatment of advanced renal cell Carcinoma with the combination bevacizumab/erlotinib/imatinib: a phase I/II trial.
- Randomized phase II trial of pemetrexed combined with either cisplatin or carboplatin in untreated extensive-stage small-cell lung Cancer.
- Randomized phase II trial of docetaxel/irinotecan and gemcitabine/irinotecan with or without celecoxib in the second-line treatment of non-small-cell lung Cancer.
- Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive coloRectal cancer after irinotecan and fluoroura...
- Cystosarcoma phyllodes. Effective therapy with cisplatin and etoposide chemotherapy.
- Inflammatory Breast carcinoma. Effective multimodal approach.
- Small-cell lung carcinoma: an Analysis of 194 consecutive patients.
- Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung Cancer after failure of standard first-line chemotherapy (BeTa): a double...
- Multicenter randomized phase II study of weekly or twice-weekly bortezomib plus rituximab in patients with relapsed or refractory follicular or marginal-zone B-Cell ly...
- Phase III trial of gemcitabine plus docetaxel versus capecitabine plus docetaxel with planned crossover to the alternate single agent in metastatic breast Cancer.
- Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refra...
- A randomized, multicenter study to determine the safety and efficacy of the immunoconjugate SGN-15 plus docetaxel for the treatment of non-small cell lung Carcinoma.
Schools
SUNY Upstate Medical University Syracuse
University Miami Hosps
Duke University Med Center
Procedures Preformed
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Anal and Rectal Cancer
- Anemia
- Bladder Cancer
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
- Aetna HMO
- Choice Plus POS II
- American Republic
- Assurant Health
- Bakery & Confectionary Union Plan
- Blue Card PPO
- Blue Care HMO
- Blue Select
- BlueDental Choice
- NetworkBlue
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- LocalPlus
- Open Access Plus
- Commercial Insurance Company
- CoreSource
- Coventry Health Care
- Employer Group PPO
- First Health (Coventry Health Care) PPO
- HealthSmart
- Humana
- Mail Handlers Benefit Plan (MHBP)
- Medicaid
- Medicare MCR
- Medico
- MultiPlan PPO
- PHCS Network PPO
- POMCO Group
- Choice Plus POS
- Neighborhood Health Partnership
- Options PPO
- United Healthcare
- Universal American
Awards
- Gulfshore Life Magazine: Top Doctors
- CMS Meaningful Use Stage 1 Certification
- Top Doctors: Florida
- Top MD
Education
-
Duke University Hospital -
Jackson Memorial Hospital - Jackson Health System -
State University of New York Upstate Medical University
Hospital
-
Lee Memorial Hospital
Drug Facts
| NPI NUMBER | 1245221993 | |
| NPPES Provider LastName | HART | |
| NPPES Provider FirstName | LOWELL | |
| NPPES Provider ZIPCode | 339057809 | |
| NPPES Provider State | FL | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 2055.0 | |
| Distinct Opioid Count | 6.0 | |
| Opioid Claim Count | 229.0 | |
| Percent Opioid Claims | 11.14 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1245221993 |
| Last Name Of The Provider | HART |
| First Name Of The Provider | LOWELL |
| View All |
Similar Doctors
|
|
Bhanuprasad Koneru, MB
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. James A. Reeves Jr., MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mohammad A. Abuel-Haija, MD |
|
|
Dr. Wilfredo Blasini, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Lawrence Seidenstein, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ryan K. Olson, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Panee Tantranond, MD |
|
|
Dr. Eric X. Wei, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Syed F. Zafar, MD |
|
|
Dr. Li Li, MD |
|
|
Van G. Rana, MB
This Doctor is OpenDoctor Recommended.
|